A new study by the Michelangelo Foundation, in collaboration with the CRUK Cambridge Institute, demonstrates that the spatial organization and interaction between tumour cells and various cell types critically influence the effect of immune checkpoint blockade.
The phase 2 DAISY trial suggests that HER2 expression is determinant of trastuzumab deruxtecan efficacy, but additional mechanisms may be involved
Oncotype DX helps to decrease discordancy in adjuvant chemotherapy recommendations in early stage breast cancer
Among selected patients with previous hormone receptor–positive early breast cancer, temporary interruption of endocrine therapy to attempt pregnancy did not rise short-term risk of breast cancer events
PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast cancer cells and suggests a new potential therapeutic target